Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law Most people hear not FDA approved and immediately think unsafe or ineffective but the reality is a lot more about economics than science. If something can't be patented, there's little incentive to Gray Market Peptides: So Much Hype, So Little Data The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Peptides and BPC 157 for Pain: PainExam Podcast Apple Podcasts